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Abstract  
Adult T-cell leukemia/lymphoma (ATL) is a distinct hematologic malignancy caused 
by human T-lymphotropic virus type 1 (HTLV-1). ATL is resistant to conventional 
chemotherapeutic agents, and currently there are only limited treatment options 
available. Although early experience of myeloablative chemoradiotherapy together 
with autologous hematopoietic stem cell rescue for ATL was associated with a high 
incidence of relapse and fatal toxicities, allogeneic hematopoietic stem cell 
transplantation (HCT) has been explored as a promising alternative treatment 
achieving long-term remission in a proportion of patients with ATL. The potential 
benefit of allogeneic HCT for ATL patients is considered to be due to the high 
immunogenicity of HTLV-1-infected cells, which was associated with the existence of 
post-transplant graft-versus-HTLV-1 and/or graft-versus-ATL effects. 
HTLV-1 was the first retrovirus to be directly associated with a human malignancy, 
and approximately 20 million people worldwide are estimated to be infected with this 
virus. Among the HTLV-1 regulatory and accessory genes, Tax transforms rodent cells 
and immortalizes human primary T cells. In addition, Tax-transgenic mice develop 
spontaneous tumors. Another HTLV-1 component gene, HTLV-1 bZIP factor (HBZ) 
promotes the proliferation of ATL cells. Transgenic mice expressing HBZ in their CD4 
T cells share many symptoms and immunological features with HTLV-1-infected 
humans. 
We document HBZ-specific CD4 T cell responses in an ATL patient after HCT, and 
have identified a novel HLA-DRB1*1501-restricted HBZ-derived naturally-presented 
minimum epitope sequence, RRRAEKKAADVA (HBZ114-125). This peptide was also 
presented on HLA-DRB1*1502, recognized by CD4 T cells. Notably, HBZ-specific CD4 
T cell responses were only observed in ATL patients after allogeneic HCT (3 of 7 
patients), but not in non-transplanted ATL (0 of 5), or in asymptomatic HTLV-1 carriers 
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(AC) (0 of 5). In addition, in one acute-type patient, HBZ-specific CD4 T cell responses 
were absent in complete remission before HCT, but became detectable after 
allogeneic HCT. We surmise that HTLV-1 transmission from mothers to infants through 
breast milk in early life induces tolerance to HBZ, and results in insufficient 
HBZ-specific T cell responses in HTLV-1 AC or ATL patients. On the other hand, after 
allogeneic HCT, the reconstituted immune system from donor-derived cells can 
recognize virus protein HBZ as foreign, and HBZ-specific immune responses are 
provoked which contribute to the graft-versus-HTLV-1 effect.
